| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 23 |
| 1 | IPILIMUMAB | 16 |
| 2 | ADALIMUMAB | 11 |
| 3 | PEMBROLIZUMAB | 10 |
| 4 | PREDNISONE | 10 |
| 5 | ACETAMINOPHEN | 7 |
| 6 | ACETAMINOPHEN 500MG | 6 |
| 7 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 6 |
| 8 | ATEZOLIZUMAB | 6 |
| 9 | PAIN RELIEVER | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | GALANTAMINE | 4 | 0.0024 |
| 1 | MIDODRINE HYDROCHLORIDE | 4 | 0.0009 |
| 2 | GOLD | 4 | 0.0007 |
| 3 | ESTRIOL | 1 | 0.0005 |
| 4 | DHEA (DEHYDROEPIANDROSTERONE) | 1 | 0.0005 |
| 5 | AVELUMAB | 2 | 0.0005 |
| 6 | OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC | 1 | 0.0004 |
| 7 | GLYCERIN SUPPOSITORY | 1 | 0.0004 |
| 8 | GLYCERIN SUPPOSITORIES | 1 | 0.0004 |
| 9 | IPILIMUMAB | 16 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 39 | 0.0004 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 16 | 0.0003 |
| 3 | CD19-directed Chimeric Antigen Receptor [EPC] | 2 | 0.0002 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |
| 5 | Autologous Cellular Immunotherapy [EPC] | 1 | 0.0002 |
| 6 | Human Immunoglobulin G [EPC] | 3 | 0.0001 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 8 | Provitamin D2 Compound [EPC] | 3 | 0.0001 |
| 9 | Antimetabolite Immunosuppressant [EPC] | 2 | 0.0001 |